Recipharm
Recipharm AB, a leading contract development and manufacturing organisation (CDMO), is headquartered in Sweden (SE) and operates extensively across Europe, North America, and Asia. Founded in 1995, Recipharm has established itself as a key player in the pharmaceutical industry, specialising in the development and production of complex drug formulations, including sterile and non-sterile products. The company offers a diverse range of services, from drug development and manufacturing to packaging and analytical services, catering to both small biotech firms and large pharmaceutical companies. Recipharm's commitment to quality and innovation has earned it a strong market position, with notable achievements in expanding its global footprint and enhancing its technological capabilities. With a focus on sustainability and efficiency, Recipharm continues to set benchmarks in the CDMO sector, making it a trusted partner for pharmaceutical companies worldwide.
DitchCarbon Score
How does Recipharm's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Recipharm's score of 75 is higher than 99% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Recipharm's reported carbon emissions
In 2024, Recipharm reported total carbon emissions of approximately 22773000 kg CO2e for Scope 1, 1600000 kg CO2e for Scope 2, and a significant 183618000 kg CO2e for Scope 3 emissions. This reflects a comprehensive approach to emissions reporting, covering all three scopes. Recipharm has set ambitious targets to reduce its carbon footprint. The company aims to achieve a 30% reduction in Scope 1 and Scope 2 emissions by 2025, using 2020 as a baseline. Additionally, they are committed to reducing absolute Scope 1 and 2 emissions by 42.1% by 2030 from a 2021 baseline, a target validated by the Science Based Targets initiative (SBTi). Furthermore, Recipharm plans to achieve net-zero emissions for Scope 1 by 2040 and for Scope 2 by 2030, with a long-term goal of net-zero emissions for Scope 3 by 2050. These commitments highlight Recipharm's dedication to sustainability within the pharmaceutical sector, aiming to transition to 100% renewable electricity by 2030 and significantly reduce emissions across its operations.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Scope 1 | 12,442,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 2 | 17,517,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 0,000,000 | 00,000,000 | 0,000,000 | 0,000,000 |
| Scope 3 | 463,000 | 000,000 | 000,000 | 000,000 | 0,000,000 | 000,000 | 00,000 | 000,000,000 | 000,000,000 | 000,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Recipharm is participating in some of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
